Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2181 to 2190 of 2733 total matches.
Rifaximin (Xifaxan) for Travelers' Diarrhea
The Medical Letter on Drugs and Therapeutics • Sep 13, 2004 (Issue 1191)
is
usually recommended. One- and two-day courses may
also be effective.
1
Azithromycin (Zithromax ...
Rifaximin (Xifaxan - Salix), a non-absorbed oral antibiotic derived from rifampin (Rifadin, and others), has been approved by the FDA for treatment of travelers' diarrhea caused by noninvasive strains of Escherichia coli in patients 12 years of age or older. It has been available in Europe since 1987.
A Combination of Oxycodone and Ibuprofen (Combunox) for Pain
The Medical Letter on Drugs and Therapeutics • Jan 02, 2006 (Issue 1225)
structurally related to morphine and codeine. It
is about 1.5 times more potent than hydrocodone and
7.0-9.5 ...
A fixed-dose combination of oxycodone 5 mg and ibuprofen 400 mg (Combunox - Forest Laboratories) is now available and is being heavily advertised for short-term treatment of moderate to severe acute pain.
A Human Papillomavirus Vaccine
The Medical Letter on Drugs and Therapeutics • Aug 14, 2006 (Issue 1241)
of sexual activity, with a cumulative incidence of 40% within
16 months.
1
Although most HPV infections ...
A recombinant quadrivalent human-papillomavirus-like particle vaccine, Gardasil (Merck), has been approved by the FDA for use in girls and women 9-26 years old to prevent diseases associated with infection with human papillomavirus (HPV) types 6, 11, 16, and 18, including genital warts, precancerous cervical, vaginal or vulvar lesions, and cervical cancer.
A Low-Dose Doxycycline (Oracea) for Rosacea
The Medical Letter on Drugs and Therapeutics • Jan 15, 2007 (Issue 1252)
to treat it.
1
Oral antibiotics tend to be effective for treatment of
papules, pustules, erythema ...
A new once-daily, low-dose oral formulation of doxycycline monohydrate (Oracea - CollaGenex) has been approved by the FDA for treatment of inflammatory papules and pustules associated with rosacea in adults.
Generic Drugs Revisited
The Medical Letter on Drugs and Therapeutics • Oct 19, 2009 (Issue 1323)
inequivalence
between brand-name and FDA-approved generic
drugs had not been reported.
1
Is that still true ...
The equivalence of generic drugs to their brand-name precursors continues to be controversial. The last Medical Letter review of this subject (2002) concluded that well-documented therapeutic inequivalence between brand-name and FDA-approved generic drugs had not been reported. Is that still true? New data have become available for some drugs.
Estetrol/Drospirenone (Nextstellis) - A New Combination Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
-year failure rates of ...
The FDA has approved a combination oral
contraceptive containing the estrogen estetrol and the
progestin drospirenone (Nextstellis – Mithra/Mayne).
Estetrol is the first new estrogen to become available
in the US in 50 years. Drospirenone is available alone
(Slynd) and in combinations with the estrogen ethinyl
estradiol for prevention of pregnancy.
An EUA for Tocilizumab (Actemra) for COVID-19
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021 (Issue 1629)
and require supplemental oxygen, mechanical
ventilation, or extracorporeal membrane oxygenation
(ECMO).1 ...
The interleukin-6 (IL-6) receptor antagonist tocilizumab (Actemra – Genentech) has received an
Emergency Use Authorization (EUA) from the FDA for IV treatment of COVID-19 in hospitalized patients ≥2
years old who are receiving a systemic corticosteroid and require supplemental oxygen, mechanical
ventilation, or extracorporeal membrane oxygenation (ECMO). Tocilizumab has been approved by the FDA
for various indications, including rheumatoid arthritis and juvenile idiopathic arthritis.
Safety of Aggressive Statin Therapy
The Medical Letter on Drugs and Therapeutics • Nov 22, 2004 (Issue 1196)
for those at moderately high
risk.
1,2
A likely consequence of these recommendations is increased use ...
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.
In Brief: Benzonatate Warning
The Medical Letter on Drugs and Therapeutics • Feb 07, 2011 (Issue 1357)
benzonatate (Tessalon Perles, and others) by
children less than 10 years old can be fatal.1 This widely ...
The FDA recently warned that accidental ingestion of the antitussive benzonatate (Tessalon Perles, and others) by children less than 10 years old can be fatal.1 This widely prescribed oral agent, which has been available in the US since 1958, can also cause severe morbidity and death in older children and adults, and not only in overdosage.Benzonatate is a polyglycol derivative structurally related to procaine and tetracaine. It acts peripherally on stretch receptors in the lower respiratory tract to suppress the cough reflex. If the patient chews or sucks the liquid-filled capsules or...
In Brief: Severe Bradycardia with Sofosbuvir and Amiodarone
The Medical Letter on Drugs and Therapeutics • Apr 13, 2015 (Issue 1466)
, and others).1 Symptomatic bradycardia
was reported following initiation of treatment with
Harvoni ...
The FDA recently announced changes in the labeling of the hepatitis C drugs Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir) to warn about a risk of serious and potentially fatal bradycardia when either drug is taken with the antiarrhythmic drug amiodarone (Cordarone, and others).1 Symptomatic bradycardia was reported following initiation of treatment with Harvoni or with Sovaldi plus simeprevir (Olysio) or the investigational antiviral drug daclatasvir in 9 patients already taking amiodarone; it occurred within 24 hours of starting hepatitis C therapy in 6 patients and within 2-12...
